Key	Positive (Final)
	Positive (Draft)
	Negative (Final)
	Negative (Draft)
	Terminated

	Drug name	Disease	Indication	TA number	NOTES			
	GROUP 1							
1	Bosutinib	Chronic myeloid leukaemia (CML)	Previously treated chronic, accelerated and blast phase Philadelphia-chromosome-positive CML when imatinib, nilotinib and dasatinib are not appropriate	<u>TA401</u>	Published August 2016			
2	Cetuximab	Head and neck cancer	Recurrent or metastatic squamous cell carcinoma of the head and neck that started in the oral cavity	<u>TA473</u>	Published August 2017			
3	Crizotinib	Non-small-cell lung cancer	Previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer	<u>TA422</u>	Published December 2016			
4	Dasatinib	Chronic myeloid leukaemia (CML)	Chronic or accelerated phase Philadelphia-chromosome-positive CML that is imatinib resistant or when imatinib cannot be tolerated	<u>TA425</u>	Published December 2016			
5	Dasatinib	Chronic myeloid leukaemia (CML)	Untreated chronic phase Philadelphia-chromosome-positive CML	<u>TA426</u>	Published December 2016			
6	Everolimus	Renal cell carcinoma	Previously treated advanced renal cell carcinoma	TA432	Published February 2017			
7	Everolimus	Breast cancer	Advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease who have had a non-steroidal aromatase inhibitor	<u>TA421</u>	Published December 2016			
8	Pemetrexed	Non-small-cell lung cancer		<u>TA402</u>	Published August 2016			
9	Radium-223 dichloride	Prostate cancer	Hormone-relapsed prostate cancer with bone metastases	<u>TA412</u>	Published September 2016			
10	Sorafenib	Hepatocellular carcinoma	Advanced hepatocellular carcinoma in people with Child-Pugh grade A liver impairment	<u>TA474</u>	Published September 2017			
11	Trastuzumab emtansine	Breast cancer	Human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane	<u>TA458</u>	Published November 2017			
			GROUP 2					
12	Abiraterone	Prostate cancer	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	<u>TA387</u>	Published April 2016			
13	Brentuximab vedotin	Hodgkin lymphoma	Relapsed or refractory CD30-positive Hodgkin lymphoma	<u>TA446</u>	Published June 2017			
14	Cabazitaxel	Prostate cancer	Hormone-relapsed metastatic prostate cancer treated with docetaxel	<u>TA391</u>	Published May 2016			
15	Cetuximab	Colorectal cancer	Untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan					
16	Cetuximab	Colorectal cancer	Untreated EGFR-expressing, RAS wild-type metastatic colorectal cancer in combination with oxaliplatin	<u>TA439</u>	Published March 2017			
17	Panitumumab	Colorectal cancer	Untreated RAS wild-type metastatic colorectal cancer in combination with irinotecan					
18	Panitumumab	Colorectal cancer	Untreated RAS wild-type metastatic colorectal cancer in combination with oxaliplatin					
19	Enzalutamide	Prostate cancer	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	<u>TA377</u>	Published January 2016			
20	Eribulin	Breast cancer	Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	<u>TA423</u>	Published December 2016			
21	Ibrutinib	Chronic lymphocytic leukaemia	Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with a 17p deletion or TP53 mutation	<u>TA429</u>	Published January 2017			
22	Pertuzumab	Breast cancer	HER2-positive metastatic or locally recurrent unresectable breast cancer	<u>TA509</u>	Published March 2018			
	GROUP 3							
23	Bortezomib	Multiple myeloma	Relapsed multiple myeloma	<u>TA453</u>	Terminated appraisal - published July 2017			
24	Brentuximab vedotin	Lymphoma	Relapsed or refractory systemic anaplastic large cell lymphoma	TA478	Published October 2017			

25	Cabozantinib	Thyroid cancer	Progressive, unresectable, locally advanced or metastatic medullary thyroid cancer	<u>TA516</u>	Published March 2018
26	Ibrutinib	non-Hodgkin lymphoma	Waldenstrom's macroglobulinaemia	<u>TA491</u>	Published November 2017
27	Ponatinib	Chronic myeloid leukaemia (CML)	Chronic, accelerated or blast phase CML	<u>TA451</u>	Published June 2017
28	Ponatinih	Acute lymphoblastic leukaemia	Philadelphia-chromosome-positive acute lymphoblastic leukaemia		
29	Regorafenib	Gastrointestinal cancer	Previously treated unresectable or metastatic gastrointestinal stromal tumours	<u>TA488</u>	Published November 2017
30	Sorafenib	Dittorontiated thurnid cancer	Progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) that does not respond to radioactive iodine	<u>ID1059</u>	Positive draft recommendation - publication expected August 2018
31	Sunitinib	Neuroendocrine tumours	Well- or moderately differentiated unresectable or metastatic neuroendocrine tumours of pancreatic origin in adults with progressive disease	<u>TA449</u>	Published June 2017
32	Vandetanib	Medullary thyroid cancer	Unresectable, locally advanced or metastatic medullary thyroid cancer	<u>ID1415</u>	Negative draft recommendation - publication expected TBC
33	Vismodegib	Basal cell carcinoma	Metastatic basal cell carcinoma, or locally advanced disease that is inappropriate for surgery or radiotherapy	<u>TA489</u>	Published November 2017

NOT APPRAISING						
Bendamustine	Lymphoma	First line	N/A			
Bendamustine	Lymphoma	Second line	N/A			
Bendamustine	Non-Hodgkin lymphoma	First line	N/A			
Bendamustine	Non-Hodgkin lymphoma	Second line	N/A			
Bevacizumab	Cervical cancer	First line	N/A			
Bevacizumab	Glioma	Third line	N/A			
Bevacizumab	Ovarian cancer	First line	N/A			
Clofarabine	Leukaemia (acute myeloblastic)	Second line				
Clofarabine	Acute lymphoblastic leukemia	Acute lymphoblastic leukaemia in patients with relapsed or refractory disease in whom the intent is to use treatment as a bridge to bone marrow transplantation	ID1033			
Lenalidomide	Myelodysplastic syndromes	First line	N/A			
Pegylated liposomal doxorubicin	Sarcoma	Any	N/A			
Nelarabine	Lymphoblastic non-Hodgkin lymphoma	Refractory T-cell lymphoblastic non-Hodgkin's lymphoma	ID1044			
Nelarabine	Acute lymphoblastic leukaemia	T-cell acute lymphoblastic leukeamia as a bridge to bone marrow transplantation	ID1034			
Temsirolimus	Renal cell carcinoma	First-line treatment of advanced renal cell carcinoma in people who have at least 3 of 6 prognostic risk factors	TA178			